We are live on ! Find out more
CINC

CinCor Pharma, Inc. Common Stock
CINC

Delisted

CINC was delisted on the 23rd of February, 2023.

Back to rankings

102 hedge funds and large institutions have $461M invested in CinCor Pharma, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 34 increasing their positions, 19 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

84% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 19

79% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 19

19% more funds holding

Funds holding: 86 → 102 (+16)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

62% less capital invested

Capital invested by funds: $1.21B → $461M (-$752M)

68% less call options, than puts

Call options by funds: $2.68M | Put options by funds: $8.47M

Holders
102
Holders Change
+16
Holders Change %
+18.6%
% of All Funds
1.64%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.06%
New
35
Increased
34
Reduced
19
Closed
19
Calls
$2.68M
Puts
$8.47M
Net Calls
-$5.79M
Net Calls Change
-$2.72M

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$37.9M
2
GPP
Great Point Partners
Connecticut
+$17.1M
3
BlackRock
BlackRock
New York
+$11.1M
4
SFM
Sphera Funds Management
Israel
+$9.79M
5
SCM
Silverarc Capital Management
Massachusetts
+$9.42M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$43.1M
2
VP
venBio Partners
California
-$35.2M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$24.7M
4
PA
Perceptive Advisors
New York
-$17.4M
5
SAM
Sectoral Asset Management
Quebec, Canada
-$6.42M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
$2.43M +$3.66M +153,498 +346%
CS
27
Candriam SCA
Luxembourg
$2.15M +$3.1M +130,000 +289%
Charles Schwab
28
Charles Schwab
California
$1.91M +$413K +17,330 +13%
UBS Group
29
UBS Group
Switzerland
$1.7M +$2.76M +115,690 +505%
Point72 Asset Management
30
Point72 Asset Management
Connecticut
$1.44M +$2.78M +116,800 New
Two Sigma Investments
31
Two Sigma Investments
New York
$1.42M +$2.76M +115,864 New
CM
32
Caption Management
Oklahoma
$1.34M +$2.6M +109,000 New
N
33
Nuveen
North Carolina
$1.05M -$8.58K -360 -0.4%
Fidelity Investments
34
Fidelity Investments
Massachusetts
$1M -$2.46M -103,092 -56%
Goldman Sachs
35
Goldman Sachs
New York
$976K +$253K +10,627 +15%
Voloridge Investment Management
36
Voloridge Investment Management
Florida
$956K +$1.85M +77,789 New
Bank of New York Mellon
37
Bank of New York Mellon
New York
$929K +$65.8K +2,759 +4%
WP
38
Woodline Partners
California
$907K -$1.22M -51,250 -41%
AA
39
AlphaCentric Advisors
Puerto Rico
$860K +$1.67M +70,000 New
CCMU
40
Cheyne Capital Management (UK)
United Kingdom
$830K +$1.61M +67,557 New
Manulife (Manufacturers Life Insurance)
41
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$823K +$544K +22,842 +50%
TD Asset Management
42
TD Asset Management
Ontario, Canada
$611K – – –
DCM
43
DAFNA Capital Management
California
$590K +$1.14M +48,000 New
AI
44
Atom Investors
Texas
$583K +$1.13M +47,401 New
D.E. Shaw & Co
45
D.E. Shaw & Co
New York
$554K -$3.16M -132,681 -75%
Swiss National Bank
46
Swiss National Bank
Switzerland
$494K – – –
Russell Investments Group
47
Russell Investments Group
United Kingdom
$492K +$955K +40,062 New
Jacobs Levy Equity Management
48
Jacobs Levy Equity Management
New Jersey
$447K +$866K +36,335 New
CSS
49
Cubist Systematic Strategies
Connecticut
$443K +$708K +29,719 +472%
PI
50
Putnam Investments
Massachusetts
$439K +$851K +35,728 New
1
2
3 4 5

CINC Hedge Fund Activity: Q4 2022 in Review

102 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in CinCor Pharma, Inc. Common Stock (CINC) for Q4 2022, worth a combined $461M — down 62% from $1.21B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new CINC positions and 19 closed out — a net gain of 16 holders — while 34 added to existing stakes and 19 trimmed.

The largest buyer was OrbiMed, adding an estimated $37.9M. The largest seller was BVF Inc, exiting entirely with an estimated $43.1M sold.

  • 102 institutional investors held CinCor Pharma, Inc. Common Stock (CINC) as of Q4 2022, up from 86 in Q3 2022.
  • Funds reported $461M of CinCor Pharma, Inc. Common Stock stock for Q4 2022, down 62% quarter-over-quarter.
  • 35 funds opened new CinCor Pharma, Inc. Common Stock positions in Q4 2022 and 19 closed out, a net change of +16 holders.
  • The largest CinCor Pharma, Inc. Common Stock buyer in Q4 2022 was OrbiMed, an estimated $37.9M added.
  • The largest CinCor Pharma, Inc. Common Stock seller in Q4 2022 was BVF Inc, an estimated $43.1M sold.

Based on aggregated 13F filings for Q4 2022.